Lifeboat Foundation

A team of researchers at the University of Texas has found NAD+ synthesis and consumption integrate glucose metabolism and adipogenic transcription during adipocyte differentiation. In their paper published in the journal Science, the group describes their research into how glucose is converted into fat in the body and what they found. Sophie Trefely and Kathryn Wellen with the University of Pennsylvania and Drexel University, respectively, offer a Perspective piece on the work done by the team in Texas in the same journal issue.

As obesity rates continue to climb around the globe, scientists continue to explore why it is happening. In addition to studying the psychological aspects involved, scientists would also like to better understand why eating too much makes people gain weight. In this new effort, the researchers looked more closely into why consuming too much glucose causes the body to produce fat.

Prior research has shown that nicotinamide adenine dinucleotide (NAD) is an important molecule that plays a role in a wide variety of physiological and pathological processes. Its oxidized form, NAD+, has also been found to act as a cofactor in metabolic pathways, and more importantly, perhaps, is consumed by various enzymes. Once consumed, NAD+ is broken down into nicotinamides and ADP-ribose. This, the researchers note, means that NAD+ must be resynthesized for normal cellular function to continue. They further note that some prior research has suggested that lower-than-normal levels of NAD+ can alter metabolism, leading in some cases to higher disease susceptibility.

Continue reading “Researchers find glycolysis links to gene transcription via NAD+” »

At Collision, start-ups showcased technologies to hire and motivate employees and build better teams. From recruiting to retention, apps are adding automation to the HR function.

In the heart of San Francisco’s Mission Bay neighborhood, which not long ago was dirt lots and warehouses, Emily Leproust is cooking up what she — and $209 million worth of investor cash — believes is the future of DNA production.

Leproust is CEO of Twist Bioscience, a 5-year-old biotech company striving to make the production of synthetic DNA — which is used in fragrances, genetically modified foods and pharmaceutical drugs — cheaper, faster and smaller.

The same lab-manufactured DNA, Leproust hopes, could also transform the way data, from music to medical records, is stored.

Continue reading “Data storage on DNA: Where Silicon Valley meets biotech” »

Every day satellites are zooming through space, snapping incredible pictures of Earth, the solar system and outer space. Here are the highlights from this week.

A new estimate of the Hubble constant – the rate at which the universe is expanding – is baffling many of the finest minds in the cosmology community.

Hannah Devlin, Science correspondent.

The VULCAN system from Made In Space combines metal deposition with machining to create metal parts.

A discussion on whether or not extended lifespans might make us paranoid about every tiniest risk.

Some months back, I read “Sapiens: A Brief History of Humankind” by Yuval Noah Harari. It’s a really good book, though it did disappoint me significantly when, after discussing the past and the present of our species, the author began glancing towards possible futures. At that point, the impartiality required of a historian, which Harari had thus far managed to keep up more or less evenly throughout the book, gave way to a subtly implied pessimism pervading, among other things, his views on future rejuvenation biotechnology.

Honestly, I wasn’t expecting him to even touch upon the subject; I was pleasantly surprised, at least until I realized that his concerns, most of which were the usual ones you’d expect, seemed to make him inclined to see rejuvenation as a plague rather than a blessing.

Continue reading “On life extension and risk aversion” »

It won’t be cheap, but your holiday plans could include a trip to the edge of Earth’s atmosphere or beyond—before the end of this year. Several space tourism companies are zeroing in on their first launch.

Bob Smith, CEO of Jeff Bezos’ Blue Origin, told CNBC: “We think we still have that possibility of getting that done this year.”

Virgin Galactic founder Richard Branson shared similar sentiments, revealing that the thing he was most excited about in 2018 was “hopefully going into space,” presumably in one of his own company’s ships. The news follows a recently restarted series of test flights after a tragic test flight crash in 2014.

Continue reading “5 Space Companies Zeroing in on First Launch of Tourists Into Orbit and Beyond” »

Read more